- Report
- August 2022
- 94 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- July 2022
- 40 Pages
China
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2022
- 40 Pages
Brazil
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2022
- 40 Pages
Argentina
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2022
- 40 Pages
Poland
From €1426EUR$1,500USD£1,198GBP
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2022
- 40 Pages
United Kingdom
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2022
- 40 Pages
Vietnam
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2022
- 40 Pages
United States
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2022
- 40 Pages
South Korea
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2022
- 40 Pages
Russia
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2022
- 40 Pages
Ireland
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2022
- 40 Pages
Germany
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2022
- 40 Pages
France
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2022
- 40 Pages
Japan
From €1426EUR$1,500USD£1,198GBP

Pompe Disease is a rare, inherited disorder caused by a deficiency of the enzyme alpha-glucosidase. This deficiency leads to the accumulation of glycogen in the lysosomes of cells, resulting in progressive muscle weakness and respiratory failure. Endocrine and Metabolic Disorders Drugs are used to treat Pompe Disease. These drugs are designed to replace the missing enzyme, allowing the body to break down the accumulated glycogen and restore normal muscle function.
The Pompe Disease Drug market is a rapidly growing segment of the Endocrine and Metabolic Disorders Drugs market. The increasing prevalence of Pompe Disease and the availability of effective treatments have driven the growth of this market. Companies in this market are focused on developing treatments that are safe and effective, as well as improving existing treatments.
Some companies in the Pompe Disease Drug market include Sanofi, Pfizer, Amicus Therapeutics, and Ultragenyx Pharmaceuticals. Show Less Read more